Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection

Figures & data

Figure 1 Diagram of the study population.

Table 1 The Demographic, Radiological and Laboratorial Characteristics of the Patients

Characteristics	Total (n=111)
Age (%)
≤ 60	79 (71.1%)
> 60	32 (28.9%)
Gender (%)
Male	65 (58.6%)
Female	46 (41.4%)
Pathology grade (%)
WHO III	50 (45.1%)
WHO IV	61 (54.9%)
Tumor size (%)
< 50mm	35 (31.6%)
≥ 50mm	76 (68.4%)
Degree of edema (%)
Mild	54 (48.7%)
Severe	57 (51.3%)
Platelet (×10^9/L)	225 (IQR 184, 259)
Neutrophils (×10^9/L)	5.18 (IQR 3.60, 6.78)
Monocytes (×10^9/L)	1.61 (IQR 1.13, 2.11)
Lymphocytes (×10^9/L)	0.40 (IQR 0.30, 0.52)
NLR	2.93 (IQR 2.09, 5.19)
MLR	0.34 (IQR 0.26, 0.42)
PLR	137.50 (IQR 102.65, 187.68)
SIRI	2.19 (IQR 1.35, 3.41)
Recurrence within six months (%)
Recurrence	36 (32.4%)
No recurrence	75 (67.6%)

Table 2 The Demographic, Radiological and Laboratorial Characteristics of the Low SII and High SII Patients

Characteristics	Low SII (n=52)	High SII (n=59)	P value
Age (%)			0.997
≤ 60	37 (71.1%)	42 (71.1%)
> 60	15 (28.9%)	17 (28.9%)
Gender (%)			0.575
Male	29 (55.8%)	36 (61.1%)
Female	23 (44.2%)	23 (38.9%)
Pathology grade (%)			<0.001
WHO III	33 (63.4%)	17 (28.9%)
WHO IV	19 (36.6%)	42 (71.1%)
Tumor size (%)			0.022
< 50mm	22 (42.3%)	13 (22.1%)
≥ 50mm	30 (57.7%)	46 (77.9%)
Degree of edema (%)			0.011
Mild	32 (61.6%)	22 (37.2%)
Severe	20 (38.4%)	37 (62.8%)
Recurrence within six months (%)			0.005
Recurrence	10 (19.2%)	26 (44.1%)
No recurrence	42 (80.8%)	33 (55.9%)
NLR	2.08 (IQR 1.64, 2.52)	5.04 (IQR 3.12, 8.77)	<0.001
MLR	0.19 (IQR 0.15, 0.25)	0.34 (IQR 0.26, 0.42)	<0.001
PLR	109.25 (IQR 86.07, 132.96)	183.33 (IQR 137.50, 256.58)	<0.001
SIRI	0.73 (IQR 0.49, 0.97)	2.19 (IQR 1.35, 3.41)	<0.001

Abbreviation: IQR, interquartile range.

Table 3 Assessment of Potential Risk Factors for Early Recurrence of Gliomas

Characteristics	Early recurrence (n=36)	No Early Recurrence (n=75)	P value
			Univariate	Multivariate
Age (%)			0.468	–
≤ 60	24 (66.7%)	55 (73.3%)
> 60	12 (33.3%)	20 (26.7%)
Gender (%)			0.973	–
Male	21 (58.3%)	44 (58.7%)
Female	15 (41.7%)	31 (41.3%)
Pathology grade (%)			0.001	–
WHO III	8 (22.2%)	42 (56.0%)
WHO IV	28 (77.8%)	33 (44.0%)
Tumor size (%)			<0.001	0.007 (OR, 4.405; 95% CI: 1.508–12.821)
< 50mm	2 (5.6%)	33 (44.0%)
≥ 50mm	34 (94.4%)	42 (56.0%)
Degree of edema (%)			0.025	–
Mild	12 (33.3%)	42 (56.0%)
Severe	24 (66.7%)	33 (44.0%)
NLR			0.011	–
≤ 3.6	17 (47.2%)	54 (72.0%)
> 3.6	19 (52.8%)	21 (28.0%)
MLR			0.381	–
≤ 0.3	16 (44.4%)	40 (53.3%)
> 0.3	20 (55.6%)	35 (46.7%)
PLR			0.010	–
≤ 126.2	9 (25.0%)	38 (50.7%)
> 126.2	27 (75.0%)	37 (49.3%)
SIRI			0.069	–
≤ 1.3	14 (38.9%)	43 (57.3%)
> 1.3	22 (61.1%)	32 (42.7%)
SII			0.005	0.017 (OR, 2.959; 95% CI: 1.209–7.194)
≤ 604.8	10 (27.8%)	42 (56.0%)
> 604.8	26 (72.2%)	33 (44.0%)

Abbreviations: IQR, interquartile range; OR, odds ratio.

Figure 2 Comparison of the AUCs for NLR, MLR, PLR, SII and SIRI in predicting early recurrence of glioma in HCG patients.

Abbreviations: AUCs, area under curves; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; SlRl, systemic inflammation response index; HCG, high grade glioma.

Table 4 Demographic, Radiological and Laboratorial Characteristics of the Patients After Propensity Score Matching

Characteristics	Low SII (n=32)	High SII (n=32)	P value
Age (%)			0.794
≤ 60	21 (65.6%)	20 (62.5%)
> 60	11 (34.4%)	12 (37.5%)
Gender (%)			0.802
Male	17 (53.1%)	16 (50.0%)
Female	15 (46.9%)	16 (50.0%)
Pathology grade (%)			0.616
WHO III	14 (43.7%)	16 (50.0%)
WHO IV	18 (56.3%)	16 (50.0%)
Tumor size (%)			0.578
< 50mm	10 (31.2%)	8 (25.0%)
≥ 50mm	22 (68.8%)	24 (75.0%)
Degree of edema (%)			0.309
Mild	15 (46.9%)	11 (34.4%)
Severe	17 (53.1%)	21 (65.6%)
Recurrence within six months (%)			0.039
Recurrence	8 (25.0%)	16 (50.0%)
No recurrence	24 (75.0%)	16 (50.0%)

Figure 3 Log rank tests were used to compare PFS (A) and OS (B) between high SII and low SII groups before PSM.

Abbreviations: PFS, progression-free survival; OS, overall survival; SII, systemic inflammation response index; PSM, propensity score matching.

Figure 4 Log rank tests were used to compare PFS (A) and OS (B) between high SII and low SII groups after PSM.

Abbreviations: PFS, progression-free survival; OS, overall survival; SII, systemic inflammation response index; PSM, propensity score matching.

Figure 5 Comparison of the AUCs for SII, tumor size and the combination of SII and tumor size in predicting early recurrence of glioma in HCG patients.

Abbreviations: AUCs, area under curves; SII, systemic immune-inflammation index; HCG, high grade glioma.